Introduction
Abdominal mass biopsy is a procedure performed by interventional radiologists to obtain tissue samples from an abnormal mass or lesion identified within the abdominal cavity. When a mass is detected on imaging, whether in a solid organ such as the liver, kidney, pancreas, adrenal gland or within the soft tissues of the abdomen, a tissue diagnosis is almost always required before any treatment can be initiated. Using real-time imaging guidance, the interventional radiologist can safely direct a biopsy needle through the skin and into the target mass, collecting tissue samples with precision while protecting surrounding structures. This minimally invasive approach has become the preferred method for characterizing abdominal masses across a wide spectrum of clinical presentations.
Understanding Abdominal Masses
An abdominal mass refers to any abnormal growth, swelling or collection of tissue detected within the abdominal cavity. Masses may arise from solid organs including the liver, spleen, kidneys, pancreas, adrenal glands and gastrointestinal tract or they may develop within the retroperitoneal space, mesentery or abdominal wall. On imaging, a mass may appear as a discrete nodule, a large infiltrative lesion or a complex cystic and solid structure. The differential diagnosis for an abdominal mass is extensive and includes primary malignancies such as hepatocellular carcinoma, renal cell carcinoma, pancreatic adenocarcinoma and gastrointestinal stromal tumors, as well as metastatic deposits, benign tumors, abscesses and inflammatory pseudotumors. Because the clinical management and prognosis differ dramatically depending on the underlying pathology, obtaining a tissue diagnosis through biopsy is a critical step in the patient’s care pathway.
Indications for the Procedure
Abdominal mass biopsy is indicated whenever a newly detected or growing abdominal mass requires histological characterization to guide management. Common indications include the diagnosis of a suspected primary hepatic or renal malignancy, tissue confirmation of metastatic disease in a patient with a known primary cancer, characterization of a pancreatic or adrenal lesion with indeterminate imaging features, evaluation of a retroperitoneal mass for sarcoma or lymphoma, and workup of an abdominal wall or soft tissue mass. The procedure is also performed in patients with systemic malignancy where biopsy of an abdominal lesion would confirm disease progression and potentially change the treatment strategy. In some cases, molecular or genetic analysis of biopsy tissue is required to identify targetable mutations and guide precision oncology decisions.
Pre-Procedure Preparation
Thorough preparation is essential before proceeding with an abdominal mass biopsy. The interventional radiologist carefully reviews all available cross-sectional imaging including CT, MRI, and PET-CT to assess the size, location and internal characteristics of the target mass. This review helps determine the safest and most representative biopsy site within the lesion, avoiding areas of central necrosis which tend to yield non-diagnostic tissue. The proximity of the mass to major vessels, bile ducts, the bowel and other structures is carefully assessed to plan the safest needle trajectory. Pre-procedure blood tests including a full blood count and coagulation profile are obtained, and any anticoagulant or antiplatelet medications are reviewed and appropriately managed. The patient is kept fasting before the procedure and detailed informed consent is obtained after explaining the purpose, technique, expected benefits and potential risks.
How the Procedure is Performed
The patient is positioned on the procedure table in the most appropriate position for access to the target mass, which may be supine, prone or lateral decubitus depending on its location. The skin overlying the planned entry point is sterilized and draped in a sterile fashion. Local anesthetic is administered to the skin and subcutaneous tissues to ensure the patient remains comfortable throughout the procedure.
Using real-time imaging guidance, the radiologist identifies the target mass and selects the optimal needle path. The trajectory is carefully planned to pass through the least amount of normal tissue, avoid major vessels and bile ducts and ideally traverse a small segment of normal organ parenchyma when biopsying lesions within solid organs such as the liver or kidney — a technique that helps reduce the risk of bleeding and tumor seeding along the needle track.
A coaxial biopsy system is the most commonly used technique. An outer introducer needle is advanced to the edge of the mass under continuous imaging guidance. Through this coaxial system, a spring-loaded core biopsy needle is passed and rapidly fired to obtain a cylindrical tissue core. The coaxial approach allows multiple samples to be taken through a single skin puncture, minimizing patient discomfort and procedural risk. Typically two to four cores are obtained from viable, non-necrotic portions of the mass to ensure adequate tissue for all required laboratory analyses. Samples are submitted for routine histopathology, immunohistochemistry, molecular profiling, cytogenetics and any other specialized tests indicated by the clinical context. Once sampling is complete, the needle is withdrawn and hemostasis is secured at the puncture site.
Post-Procedure Monitoring and Recovery
After the procedure, the patient is moved to a recovery area for monitoring of vital signs and the puncture site, typically for one to two hours. Most patients tolerate the procedure well and are discharged home on the same day. They are advised to rest for the remainder of the day and avoid heavy physical activity for twenty-four hours. Instructions are provided to monitor the puncture site and to seek medical attention if they experience worsening abdominal pain, fever, significant swelling or any signs of bleeding. Pathology results are generally available within two to five working days, and the patient is followed up by the referring clinical team to discuss the findings and plan further management.
Risks and Complications
Abdominal mass biopsy is a well-established procedure with an excellent safety record when performed by an experienced interventional radiologist using imaging guidance. Minor complications include transient pain at the biopsy site and small hematoma formation, both of which typically resolve without treatment. More significant complications are uncommon and include clinically significant hemorrhage, infection, pneumothorax when biopsying upper abdominal lesions close to the diaphragm, bile leak following liver biopsy and injury to adjacent organs. The theoretical risk of tumor seeding along the needle track exists but is extremely rare with modern fine-gauge coaxial needle systems and careful technique.
Diagnostic Accuracy and Clinical Importance
Image-guided core needle biopsy of abdominal masses achieves diagnostic accuracy rates of over 90 percent in most published series. Beyond providing a histological diagnosis, the tissue obtained through this procedure increasingly serves as the foundation for advanced molecular testing. In the current era of precision oncology, identifying specific genetic mutations, receptor expression profiles and molecular signatures from biopsy tissue directly influences the selection of targeted therapies, immunotherapy agents and clinical trial eligibility. A single well-performed biopsy can therefore provide information that shapes the entire course of a patient’s cancer treatment.
Conclusion
Abdominal mass biopsy performed by an interventional radiologist is a highly effective, safe and minimally invasive procedure that provides essential diagnostic information for patients with abdominal lesions. By combining precise imaging guidance with modern biopsy techniques, interventional radiologists can reliably obtain high-quality tissue samples from virtually any accessible abdominal mass with minimal risk and maximum accuracy. This procedure sits at the heart of the modern oncology diagnostic pathway, delivering the tissue diagnosis that every subsequent treatment decision depends upon.